tirzepatide shortage ends Eli Lilly's Weight-Loss Drug Zepbound Is Officially Over: FDA Tirzepatide Shortage Resolved? FDA Says
Description
doi:10.1056/NEJMoa2401234
This means that, for some patients, Wegovy is now a more cost-effective GLP-1 treatment option for weight management
The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy
Adverse effects associated with selective serotonin reuptake inhibitors and antidepressants: a meta-analysis
RELATED STORY | Americas Poison Centers: 69% rise in calls from drugs that cause weight loss The decision marks a victory for drugmaker Eli Lilly, which challenged the FDAs 2022 decision to officially declare a shortage of tirzepatide
